Suspended, active non-recruiting and recruiting oncological phase 1, 2, 3 clinical trials respectively throughout the world from the beginning of pandemic to the first six months of 2022 (30/01/2020 to 30/06/2022)
| Study status | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
| Suspended | 33 | 41 | 5 |
| Active, non-recruiting | 236 | 357 | 118 |
| Recruiting | 2,368 | 3,474 | 818 |
| Total | 3,592 | 5,466 | 1,464 |
RB and ZB: Conceptualization. ZB, AL, MB, and VA: Methodology. VA, GR, VT, LM, and CC: Data curation. VA and ZB: Writing—original draft, Writing—review & editing. RB: Supervision. All authors have read and agreed to the published version of the manuscript.
RB is a consultant/advisory board member for AstraZeneca, Boehringer Ingelheim, Novartis, MSD, Otsuka, Eli-Lilly, Roche, Amgen, GSK, Eisai, Bristol Myers Squibb. ZB is a consultant/advisory board member for Daichii Sanchyo. All other authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2023.